SG11201704917XA - Radio-pharmaceutical complexes - Google Patents
Radio-pharmaceutical complexesInfo
- Publication number
- SG11201704917XA SG11201704917XA SG11201704917XA SG11201704917XA SG11201704917XA SG 11201704917X A SG11201704917X A SG 11201704917XA SG 11201704917X A SG11201704917X A SG 11201704917XA SG 11201704917X A SG11201704917X A SG 11201704917XA SG 11201704917X A SG11201704917X A SG 11201704917XA
- Authority
- SG
- Singapore
- Prior art keywords
- radio
- pharmaceutical complexes
- complexes
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422512 | 2014-12-17 | ||
| PCT/EP2015/079773 WO2016096843A1 (en) | 2014-12-17 | 2015-12-15 | Radio-pharmaceutical complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704917XA true SG11201704917XA (en) | 2017-07-28 |
Family
ID=54884033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704917XA SG11201704917XA (en) | 2014-12-17 | 2015-12-15 | Radio-pharmaceutical complexes |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20170340759A1 (en) |
| EP (1) | EP3233137A1 (en) |
| JP (2) | JP6821569B2 (en) |
| KR (1) | KR20170094223A (en) |
| CN (1) | CN107278155B (en) |
| AR (1) | AR103063A1 (en) |
| AU (2) | AU2015367722A1 (en) |
| BR (1) | BR112017012841A2 (en) |
| CA (1) | CA2970841A1 (en) |
| CL (1) | CL2017001592A1 (en) |
| CO (1) | CO2017005975A2 (en) |
| CR (1) | CR20170256A (en) |
| CU (1) | CU24493B1 (en) |
| DO (1) | DOP2017000143A (en) |
| EA (1) | EA201791350A9 (en) |
| EC (1) | ECSP17038089A (en) |
| IL (1) | IL252244B (en) |
| JO (1) | JOP20150319B1 (en) |
| MA (1) | MA41176A (en) |
| MX (1) | MX2017008093A (en) |
| MY (1) | MY194190A (en) |
| NI (1) | NI201700076A (en) |
| PE (2) | PE20171181A1 (en) |
| PH (1) | PH12017501125A1 (en) |
| SG (1) | SG11201704917XA (en) |
| TN (1) | TN2017000255A1 (en) |
| TW (1) | TWI654179B (en) |
| UA (1) | UA125369C2 (en) |
| UY (1) | UY36453A (en) |
| WO (1) | WO2016096843A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017162555A1 (en) * | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Radio-pharmaceutical complexes |
| MX2018015340A (en) * | 2016-06-10 | 2019-03-28 | Bayer Pharma AG | Radio-pharmaceutical complexes. |
| CA3054248A1 (en) | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| EP3600452A4 (en) * | 2017-03-30 | 2020-11-18 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| CA3110754A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
| CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
| EP3927339A1 (en) | 2019-02-22 | 2021-12-29 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
| US20230072421A1 (en) | 2019-07-25 | 2023-03-09 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
| TW202216771A (en) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | Ccr8 antibodies for therapeutic applications |
| JP2024503908A (en) | 2021-01-22 | 2024-01-29 | バイエル アクチェンゲゼルシャフト | LRRC15 antibody and its conjugate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158804B2 (en) * | 2007-01-11 | 2012-04-17 | Ge Healthcare As | Chelating agents |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201208309D0 (en) * | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2015
- 2015-12-14 MA MA041176A patent/MA41176A/en unknown
- 2015-12-15 PE PE2017001093A patent/PE20171181A1/en unknown
- 2015-12-15 TN TN2017000255A patent/TN2017000255A1/en unknown
- 2015-12-15 SG SG11201704917XA patent/SG11201704917XA/en unknown
- 2015-12-15 UA UAA201707516A patent/UA125369C2/en unknown
- 2015-12-15 PE PE2022002504A patent/PE20230829A1/en unknown
- 2015-12-15 JP JP2017532833A patent/JP6821569B2/en active Active
- 2015-12-15 EP EP15813024.5A patent/EP3233137A1/en active Pending
- 2015-12-15 WO PCT/EP2015/079773 patent/WO2016096843A1/en active Application Filing
- 2015-12-15 MX MX2017008093A patent/MX2017008093A/en unknown
- 2015-12-15 US US15/537,127 patent/US20170340759A1/en not_active Abandoned
- 2015-12-15 BR BR112017012841A patent/BR112017012841A2/en not_active Application Discontinuation
- 2015-12-15 CU CU2017000082A patent/CU24493B1/en unknown
- 2015-12-15 CR CR20170256A patent/CR20170256A/en unknown
- 2015-12-15 EA EA201791350A patent/EA201791350A9/en unknown
- 2015-12-15 AU AU2015367722A patent/AU2015367722A1/en not_active Abandoned
- 2015-12-15 CN CN201580069545.0A patent/CN107278155B/en active Active
- 2015-12-15 CA CA2970841A patent/CA2970841A1/en active Pending
- 2015-12-15 MY MYPI2017702228A patent/MY194190A/en unknown
- 2015-12-15 KR KR1020177016311A patent/KR20170094223A/en not_active Application Discontinuation
- 2015-12-16 JO JOP/2015/0319A patent/JOP20150319B1/en active
- 2015-12-17 TW TW104142567A patent/TWI654179B/en active
- 2015-12-17 UY UY0001036453A patent/UY36453A/en not_active Application Discontinuation
- 2015-12-17 AR ARP150104130A patent/AR103063A1/en unknown
-
2017
- 2017-05-11 IL IL252244A patent/IL252244B/en active IP Right Grant
- 2017-06-15 PH PH12017501125A patent/PH12017501125A1/en unknown
- 2017-06-16 CL CL2017001592A patent/CL2017001592A1/en unknown
- 2017-06-16 DO DO2017000143A patent/DOP2017000143A/en unknown
- 2017-06-16 NI NI201700076A patent/NI201700076A/en unknown
- 2017-06-16 CO CONC2017/0005975A patent/CO2017005975A2/en unknown
- 2017-06-19 EC ECIEPI201738089A patent/ECSP17038089A/en unknown
-
2021
- 2021-01-05 JP JP2021000454A patent/JP7160961B2/en active Active
- 2021-01-15 US US17/150,811 patent/US20210322583A1/en not_active Abandoned
- 2021-04-29 AU AU2021202665A patent/AU2021202665B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263538A (en) | Radio-pharmaceutical complexes | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| IL252244A0 (en) | Radio-pharmaceutical complexes | |
| GB201402431D0 (en) | Compounds | |
| GB201404987D0 (en) | Compounds | |
| GB201406591D0 (en) | Compounds | |
| GB201504784D0 (en) | Complexes | |
| GB201406956D0 (en) | Compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201413695D0 (en) | Compound | |
| GB201412238D0 (en) | Compound | |
| ZA201804206B (en) | Amylose-lipid complexes | |
| GB201613876D0 (en) | Complexes | |
| GB201413216D0 (en) | Anti-Dandruff Composition | |
| GB201407694D0 (en) | Compound | |
| PL3224355T3 (en) | Enzyme-inhibitor complexes | |
| IL261329B (en) | Radio-pharmaceutical complexes | |
| GB201508480D0 (en) | Cancer | |
| GB201407695D0 (en) | Compounds | |
| IL248782A0 (en) | Treatment regimen tiacumicin compound | |
| SG11201610339YA (en) | Metal complexes | |
| GB201418709D0 (en) | Compound | |
| GB201408735D0 (en) | Application coordination | |
| GB201407693D0 (en) | Compound | |
| GB201405361D0 (en) | Compounds |